New insights into the comorbid conditions of Turner syndrome: results from a long-term monocentric cohort study
- PMID: 35907176
- PMCID: PMC9646560
- DOI: 10.1007/s40618-022-01853-z
New insights into the comorbid conditions of Turner syndrome: results from a long-term monocentric cohort study
Abstract
Purpose: Many questions concerning Turner syndrome (TS) remain unresolved, such as the long-term complications and, therefore, the optimal care setting for adults. The primary aim of this long-term cohort study was to estimate the incidence of comorbid conditions along the life course.
Methods: A total of 160 Italian patients with TS diagnosed from 1967 to 2010 were regularly and structurally monitored from the diagnosis to December 2019 at the University Hospital of Bologna using a structured multidisciplinary monitoring protocol.
Results: The study cohort was followed up for a median of 27 years (IQR 12-42). Autoimmune diseases were the comorbid condition with the highest incidence (61.2%), followed by osteoporosis and hypertension (23.8%), type 2 diabetes (16.2%) and tumours (15.1%). Median age of onset ranged from 22 years for autoimmune diseases to 39 years for type 2 diabetes. Malignant tumours were the most prominent type of neoplasm, with a cumulative incidence of 11.9%. Papillary thyroid carcinoma was the most common form of cancer, followed by skin cancer and cancer of the central nervous system. Only one major cardiovascular event (acute aortic dissection) was observed during follow-up. No cases of ischaemic heart disease, heart failure, stroke or death were recorded.
Conclusions: This cohort study confirms the need for continuous, structured and multidisciplinary lifelong monitoring of TS, thus ensuring the early diagnosis of important comorbid conditions, including cancer, and their appropriate and timely treatment. In addition, these data highlight the need for the increased surveillance of specific types of cancer in TS, including thyroid carcinoma.
Keywords: Cancer; Cardiovascular events; Osteoporosis; Turner syndrome; Type 2 diabetes.
© 2022. The Author(s).
Conflict of interest statement
This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector. The corresponding author states that there is no conflict of interest.
Figures
Similar articles
-
Clinical practice in Turner syndrome.Nat Clin Pract Endocrinol Metab. 2005 Nov;1(1):41-52. doi: 10.1038/ncpendmet0024. Nat Clin Pract Endocrinol Metab. 2005. PMID: 16929365 Review.
-
Autoimmune thyroid diseases in 65 Japanese women with Turner syndrome.Endocr J. 2009;56(8):983-6. doi: 10.1507/endocrj.k09e-141. Epub 2009 Aug 11. Endocr J. 2009. PMID: 19671996
-
Italian cancer figures--Report 2015: The burden of rare cancers in Italy.Epidemiol Prev. 2016 Jan-Feb;40(1 Suppl 2):1-120. doi: 10.19191/EP16.1S2.P001.035. Epidemiol Prev. 2016. PMID: 26951748
-
Aortic dilatation and dissection in Turner syndrome: what we know, what we are unclear about and what we should do in clinical practice?Int J Adolesc Med Health. 2014;26(4):469-88. doi: 10.1515/ijamh-2013-0336. Int J Adolesc Med Health. 2014. PMID: 24887949 Review.
-
New insights on diabetes in Turner syndrome: results from an observational study in adulthood.Endocrine. 2018 Mar;59(3):651-660. doi: 10.1007/s12020-017-1336-z. Epub 2017 Jun 7. Endocrine. 2018. PMID: 28593616
Cited by
-
Elevated levels of neutrophils with a pro-inflammatory profile in Turner syndrome across karyotypes.NPJ Genom Med. 2025 Feb 6;10(1):9. doi: 10.1038/s41525-025-00467-7. NPJ Genom Med. 2025. PMID: 39915521 Free PMC article.
-
Components of the metabolic syndrome in girls with Turner syndrome treated with growth hormone in a long term prospective study.Front Endocrinol (Lausanne). 2023 Jul 11;14:1216464. doi: 10.3389/fendo.2023.1216464. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37497348 Free PMC article.
-
Transition from pediatric to adult care in patients with Turner syndrome in Italy: a consensus statement by the TRAMITI project.J Endocrinol Invest. 2024 Jul;47(7):1585-1598. doi: 10.1007/s40618-024-02315-4. Epub 2024 Feb 20. J Endocrinol Invest. 2024. PMID: 38376731 Free PMC article.
-
Exploring the interplay of karyotype, hormones, sexuality, and body image perception in individuals with Turner syndrome.J Endocrinol Invest. 2025 May;48(5):1225-1236. doi: 10.1007/s40618-024-02521-0. Epub 2025 Feb 13. J Endocrinol Invest. 2025. PMID: 39946049 Free PMC article.
-
Clinical practice guidelines for the care of girls and women with Turner syndrome.Eur J Endocrinol. 2024 Jun 5;190(6):G53-G151. doi: 10.1093/ejendo/lvae050. Eur J Endocrinol. 2024. PMID: 38748847 Free PMC article.
References
-
- Saenger P, Wikland KA, Conway GS, Davenport M, Gravholt CH, Hintz R, Hovatta O, Hultcrantz M, Landin-Wilhelmsen K, Lin A, et al.; Fifth International Symposium on Turner Syndrome. Recommendations for the diagnosis and management of Turner Syndrome. J Clin Endocrinol Metab. 2001; 86: 3061–3069. 10.1210/jcem.86.7.7683. - PubMed
-
- Freriks K, Timmermans J, Beerendonk CCM, Verhaak CM, Netea-Maier RT, Otten BJ, Braat DDM, Smeets DFCM, Kunst DHPM, Hermus ARMM, et al. Standardized multidisciplinary evaluation yields significant previously undiagnosed morbidity in adult women with Turner Syndrome. J Clin Endocrinol Metab. 2011;96:E1517–E1526. doi: 10.1210/jc.2011-0346. - DOI - PubMed
-
- Fiot E, Zénaty D, Boizeau P, Haignere J, Dos Santos S, Léger J, French Turner Syndrome Study Group. X chromosome gene dosage as a determinant of congenital malformations and of age-related comorbidity risk in patients with Turner Syndrome, from childhood to early adulthood. Eur J Endocrinol 2019;180: 397–406. 10.1530/EJE-18-0878. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical